Can’t Meet The Brexit Deadline? EU Regulators To Find ‘Flexible Solutions’ For Industry
With less than 11 months left to prepare for Brexit, companies with drugs in Europe’s decentralized and mutual recognition procedures are being urged to tell regulators if they are struggling to make the necessary changes by the March 2019 deadline for the UK to leave the EU.
You may also be interested in...
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.
The risk of developing meningioma with cyproterone-containing medicines is rare, but it is serious enough to merit restrictions on how such products are used, according to the European Medicines Agency.
The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.